Business Wire

Thales Wins Google Cloud Technology Partner of the Year Security – Data Protection Award

Share

Thales has been selected as the Google Cloud Technology Partner of the Year in the Security – Data Protection category. Thales was selected alongside a global field of top Google Cloud partners for excellence in developing and implementing customer solutions based on Google Cloud’s technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230829348216/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

The Thales and Google Cloud collaboration addresses the needs of organizations around the world that are facing ever-increasing security, sovereignty, and performance requirements for their cloud deployments. With many years of cybersecurity expertise, Thales provides the level of trust and security required for customers around the world to move to the cloud, while maintaining the necessary level of control. By combining Thales’ platform expertise with Google Cloud’s enterprise-grade solutions and cutting-edge infrastructure, the two companies work closely on a number of broad data security initiatives.

Thales, in its constant search of excellence in its security portfolio, recently announced a new collaboration to develop data security capabilities and bring additional AI-powered features to users of its CipherTrust Data Security platform. This is powered by Google Cloud’s Vertex AI machine learning capabilities, to discover, classify and protect sensitive data in the cloud. The machine learning functionality helps to automate fundamental tasks for customers and ensure their sensitive cloud-hosted data remains protected.

Since late 2022, Thales’ CipherTrust Cloud Key Manager has also supported Bring Your Own Key (BYOK) initiatives, including those for Google Cloud and Google Workspace. Thales and Google Cloud have also collaborated to operate a sovereign cloud joint venture (S3NS) for Google Cloud customers in France who seek to meet stringent data sovereignty requirements, such as those applicable to state and critical infrastructure organizations.

Thales has built a structured cloud offering for companies that want to meet the most demanding data protection standards. In France, S3NS, the joint venture between Thales and Google Cloud, aims to offer French companies and public institutions a solution providing the equivalent of Google Cloud , compliant with the “SecNumCloud” label, a certification from the French information systems security agency (ANSSI). To date, SecNumCloud has the highest level of protection in France, excluding the protection of national defense secrets, and in Europe. S3NS has a first offering already available that offers additional guarantees & controls, such as data location in Europe and external encryption managed by S3NS (based on Thales technology).

“Google Cloud’s partner awards recognize the significant impact and customer success that our partners have driven over the past year," said Kevin Ichhpurani, Corporate Vice President, Global Ecosystem and Channels at Google Cloud. "We're delighted to recognize Thales as a 2023 Google Cloud Partner Award winner, and look forward to a continued strong partnership in support of our mutual customers."

Sebastien Cano, Senior Vice President of Cloud Protection and Licensing activities at Thales, commented: “We are very proud of our ongoing relationship with Google Cloud and this latest award recognises the brilliant work we’ve been doing with them across a range of projects. Together we are helping customers around the world discover, classify and protect their data more efficiently, and ensure their move to the cloud is as secure and compliant as possible.”

Thales is also participating at Google Cloud Next, which is taking place from 29-31 August 2023. Some of the sessions include:

How global leaders are addressing digital sovereignty requirements, with Cyprien Falque, CEO of S3NS More details about the event, which will be available to watch both live and on-demand online, can be found here.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

 

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

 

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

 

PLEASE VISIT

Thales Group
Cloud Protection & Licensing Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye